Friday, 24 May 2019

Perrigo to launch its AB rated generic Zovirax cream

07 February 2019 | News

The Cream, 5% (acyclovir cream, 5%) is developed in collaboration with Sol-Gel Technologies Ltd.

Perrigo Company plc has announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Zovirax® Cream, 5% (acyclovir cream, 5%) developed in collaboration with Sol-Gel Technologies Ltd. The Company anticipates launching the product this month. 

Annual market sales for the twelve months ending December 2018 were approximately $92 million as measured by IQVIA™.

Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This final approval and first to market launch is another example of our long-term investment in new products, the team's impressive execution skills and our solid collaboration with SolGel.  We stay committed to providing affordable treatment options for patients in important extended topical categories."

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Will stem cell therapy market witness highest growth in Asia by 2020?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls